Journal profile · Medicine-Psychiatry and Mental Health
Biomarkers in Neuropsychiatry
ISSN 2666-1446 · Elsevier · Netherlands
Biomarkers in Neuropsychiatry: fully open access; APC about USD 3,140; review about 133 days (submission to acceptance, publisher); 16 articles in 2025; indexed in Scopus.
Scope
Aims, scope and focus
Biomarkers in Neuropsychiatry is published by Elsevier. By OpenAlex counts of its recent articles, its largest topics are Schizophrenia research and treatment, Dementia and Cognitive Impairment Research and Treatment of Major Depression, together about 37.1% of its articles. Its main subfields are Psychiatry and Mental health. (generated from OpenAlex topic counts and CAS ranking data)
Biomarkers in Neuropsychiatry is an international, peer-review, rapid-publication and open access journal published by Elsevier. It is dedicated to disseminating original data, systematic reviews and meta-analyses focusing on neurobiologic, therapeutic or prognostic biomarkers associated with all brain disorders, neurologic and/or psychiatric. The Journal will consider submissions related to a wide array of genetic, molecular, neuroimaging (MRI, MRS, fMRI and DTI), neurophysiological, neurochemical, endocrinological and immunological biomarkers, related to brain structure or function in all neuropsychiatric disorders.The Journal encourages interdisciplinary research collaboration across multiple scientific disciplines because that often facilitates the generation of breakthrough insights and novel biomarkers.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Psychiatry and Mental Health
Editor-in-chief Brett ClementzPublisher website
Editorial board by country: 1 in mainland China (about 2%); most named United States 29, Australia 3, Brazil 3, United Kingdom 2, Mainland China 1 (42 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Schizophrenia research and treatmentMedicine18.7%
- Dementia and Cognitive Impairment ResearchMedicine11.2%
- Treatment of Major DepressionMedicine7.2%
- Mental Health and PsychiatryArts and Humanities6.4%
- Neurotransmitter Receptor Influence on BehaviorNeuroscience4.8%
- Alzheimer's disease research and treatmentsMedicine4.8%
- Tryptophan and brain disordersNeuroscience4.8%
- Glaucoma and retinal disordersMedicine3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Biochemistry (medical) | Q2 | 33/78 | 58th |
| Psychiatry and Mental Health | Q2 | 250/580 | 56th |
| Neurology (clinical) | Q2 | 197/403 | 51st |
| Clinical Biochemistry | Q3 | 71/124 | 43rd |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 3.9LetPub ·
- CiteScore (publisher)
- 3.9Publisher website ·
- SJR 2026-06
- 0.8LetPub ·
- SNIP 2026-06
- 0.59LetPub ·
- h-index
- 20OpenAlex ·
- i10-index
- 47OpenAlex ·
- 2-year mean citedness
- 3.17OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Articles by year OpenAlex count · 135 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 8 | 8 | 313 |
| 2025 | 16 | 16 | 361 |
| 2024 | 35 | 35 | 295 |
| 2023 | 22 | 22 | 203 |
| 2022 | 13 | 13 | 176 |
| 2021 | 16 | 16 | 125 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
Too few articlesOnly 1 articles from the last 24 months carry both submission and acceptance dates, too few for a median
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Figures by source
- Average review time (community reports)
- about 7 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 111 daysPublisher website ·
- Submission to acceptance
- 133 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
- Submission to publication (journal-reported)
- about 20 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,140 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 2,930 / EUR 2,740 / GBP 2,350 / JPY 363,410 | — | — | |
| LetPub | USD 1,840 | Yes | — | |
| Publisher website | USD 1,715 / USD 3,430 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- APA
- Highlights
- Optional
Article types accepted1
- case reportFor case reports you are required to follow CARE guidelines and provide the CARE checklist at manuscript submission.Read the CARE guidelinesFollow the CARE chec…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Publication ethics
Follow Elsevier's Publishing Ethics Policy Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized peer review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed; does not count as prior publication Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2666-1446
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Biomarkers in Neuropsychiatry
How long does peer review take at Biomarkers in Neuropsychiatry?
The publisher reports about 133 days (submission to acceptance); authors report an average review time of about 7 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Biomarkers in Neuropsychiatry?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: APA; Highlights: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Biomarkers in Neuropsychiatry based?
Of the 42 board members whose country the journal's board page names, 1 (about 2%) are in mainland China; the countries named most often are United States (29), Australia (3) and Brazil (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Biomarkers in Neuropsychiatry?
According to LetPub and DOAJ records, Biomarkers in Neuropsychiatry is indexed in Scopus and DOAJ.
Is Biomarkers in Neuropsychiatry open access, and what is the APC?
Biomarkers in Neuropsychiatry is a fully open-access journal. APC about USD 3,140.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .